Business Context and Reporting Period
This Form 8-K Current Report, dated March 14, 2016, details a material definitive agreement entered into by Capricor Therapeutics, Inc. The filing announces a registered direct offering and a concurrent private placement of securities to raise capital.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.1 million from the sale of securities.
- Common Stock Issued: 1,692,151 shares at a purchase price of $2.40 per share.
- Warrants Issued: Warrants to purchase up to 50% of the shares purchased in the public offering.
- Warrant Terms: Exercise price of $4.50 per share; exercisable starting September 16, 2016; expiration three years from issuance.
- Transaction Costs: Placement agent fee of approximately $73,000 (6.0% of gross proceeds), plus reimbursement of expenses up to $5,000 and legal fees up to $10,000.
- Insider Participation: Certain officers and directors are purchasing securities, paying $0.125 per warrant share upon closing.
Material Changes and Outlook
The filing does not provide comparative financial data (revenue, profit, cash flow) or year-over-year changes as it is a transaction-specific report rather than a periodic financial statement. The primary material change is the dilution of existing shareholders due to the issuance of new shares and warrants. The closings of the offerings were expected to occur on or about March 15, 2016.
Management Commentary and Risks
- Registration Rights: The Company agreed to file a registration statement for the resale of warrant shares within 90 calendar days of closing.
- Liquidity Constraints: Warrants are unregistered and subject to resale restrictions under Section 4(a)(2) of the Securities Act or Rule 144 until a registration statement is effective.
- Use of Proceeds: The filing text does not explicitly state the intended use of the $4.1 million in proceeds.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received.
- Confirm the total number of outstanding shares post-closing to assess dilution impact.
- Review the Company's subsequent filings to confirm the filing and effectiveness of the registration statement for warrant shares.
- Check the Company's most recent 10-K or 10-Q for current cash balances and burn rate to understand the runway provided by this $4.1 million raise.